ReviewNeurourology and urodynamics2026
How Can We Personalize the Delivery of Onabotulinumtoxin-A for Patients With Neurogenic Lower Urinary Tract Dysfunction?
Review in Neurourology and urodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsNeurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin-A (BoNT-A) is approved for NLUTD in patients who have an inadequate response to or intolerance of oral pharmacologic therapy (with beta-3 agonists and/or antimuscarinics) for urinary frequency, urgency, urgency incontinence, and/or impaired compliance. Modifications of its use, including dose, injection location, number of injections, setting of procedure, combination therapy with oral agents, and use among different patient populations have since been explored. Here, we aim to review the literature on BoNT-A in NLUTD with a focus on unique neurologic patient groups as well as patient and technical factors to inform personalized treatment strategies.
methodsWe performed a narrative review evaluating the existing literature on BoNT-A in NLUTD, focusing on outcomes across neurologic etiologies, and variation in patient-specific and technical factors.
resultsAcross neurologic etiologies, BoNT-A improves quality of life and urodynamic parameters with low rates of adverse effects. Patient factors, including baseline voiding status, ability to self-catheterize, and age are important considerations in treatment selection and initial dosing of BoNT-A. Technical modifications such as reduced injection sites or trigone-including templates have been suggested to reduce adverse effects or improve efficacy but require further study.
conclusionsBoNT-A is an established therapy for NLUTD. Individualized treatment strategies that account for patients' neurologic etiology and functional status are beneficial in optimizing outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.